Prothena Corp Public (PRTA) EBIT Margin (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly EBIT Margin of 58.8% for Q1 2026, up 237778.0% year-over-year from N/an in Q1 2025, and up 100.05% quarter-over-quarter from 115252.38% in Q4 2025.
Prothena Corp Public (PRTA) EBIT Margin (2012 - 2026) Analysis & Trends
Prothena Corp Public's EBIT Margin history runs 15 years deep, the most recent figure standing at 58.8% for Q1 2026.
- In Q1 2026, EBIT Margin rose 237778.0% year-over-year to 58.8%; the TTM figure through Mar 2026 stood at 205.43% (down 10493.0% YoY), while the FY2025 annual figure was 2216.44%, down 210208.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 58.8%, up from 115252.38% in the prior quarter.
- The five-year high for EBIT Margin was 58.8% in Q1 2026, with the low at 163056.0% in Q1 2024.
- The 5-year median for EBIT Margin is 2596.82% (2023), against an average of 19588.65%.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin sank 16045918 bps in 2024, then surged 16073701 bps in 2025.
- Prothena Corp Public's EBIT Margin stood at 0.14% in 2022, then tumbled by 17227855 bps to 24846.52% in 2023, then soared by 88 bps to 3056.85% in 2024, then tumbled by 3670 bps to 115252.38% in 2025, then surged by 100 bps to 58.8% in 2026.
- Business Quant data shows PRTA's EBIT Margin at 58.8% in Q1 2026, 115252.38% in Q4 2025, and 1666.25% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | -2,089.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,089.21% |
| Mar 31, 2026 | 58.80% |
| Dec 31, 2025 | -115,252.38% |
| Sep 30, 2025 | -1,666.25% |
| Jun 30, 2025 | -1,914.39% |
| Mar 31, 2025 | -2,318.99% |
| Dec 31, 2024 | -3,056.85% |
| Sep 30, 2024 | -6,857.01% |
| Jun 30, 2024 | 44.22% |
| Mar 31, 2024 | -163,056.00% |
| Dec 31, 2023 | -24,846.52% |
| Sep 30, 2023 | 12.15% |
| Jun 30, 2023 | -1,654.74% |
| Mar 31, 2023 | -2,596.82% |
| Dec 31, 2022 | -0.14% |
| Sep 30, 2022 | -3,317.86% |
| Jun 30, 2022 | -3,293.37% |
| Mar 31, 2022 | -3,290.89% |
| Dec 31, 2021 | -2,823.55% |
| Sep 30, 2021 | 78.48% |